Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Centers for Disease Control and Prevention
Cold-adapted influenza A H9N2 reassortant is influenza vaccine candidate
January 14th, 2004
Researchers have characterized a cold-adapted influenza A H9N2 reassortant for use as a live pandemic influenza virus vaccine candidate. According to recent research published in the journal Vaccine, "H9N2 subtype influenza A viruses have been identified in avian species worldwide and were isolated from humans in 1999, raising concerns about their pandemic potential and prompting the development of candidate vaccines to protect humans against this subtype of influenza A virus. Reassortant H1N1 and H3N2 human influenza A viruses with the internal genes of the influenza A/Ann Arbor/6/60 (H2N2) (AA) cold-adapted (ca) virus have proven to be attenuated and safe as...
Source: Biotech Week (2004-01-14)
|
